Bundle for pediatric COVID-19 sepsis

Jaime Fernández-Sarmiento1, Werther Brunow de Carvalho2

  • 1Universidad de la Sabana, Fundación Cardioinfantil-Instituto de Cardiologia, Departament of Pediatric Critical Care Medicine - Bogotá, Colombia.

Revista Da Associacao Medica Brasileira (1992)
|July 14, 2021
PubMed

Insights

This study proposes a sepsis bundle for severe COVID-19 in children, focusing on early recognition and interventions like oxygen therapy and mechanical ventilation to reduce mortality. This strategy aims to improve outcomes in critical COVID-19 cases.

Area of Science:

  • Critical Care Medicine
  • Pediatric Infectious Diseases
  • Respiratory Medicine

Background:

  • Severe COVID-19 infection is associated with high mortality rates, often due to multiple organ failure.
  • Pathophysiological hallmarks include elevated serum ferritin, D-dimer, and C-reactive protein, indicative of macrophage activation syndrome.
  • Inadequate resolution of the host's inflammatory response contributes to severe outcomes.

Purpose of the Study:

  • To propose a comprehensive sepsis bundle for managing severe COVID-19 in children.
  • To outline key components of the proposed bundle for early intervention and clinical course modification.

Main Methods:

  • The study proposes a multi-component bundle for COVID-19 sepsis management.
  • Key elements include early recognition, protective measures (handwashing, isolation), oxygen therapy, and early invasive mechanical ventilation.
  • The strategy is informed by successful bundle implementations in other sepsis etiologies.

Main Results:

  • The proposed bundle integrates early recognition with critical care interventions.
  • It aims to address the inflammatory cascade and organ failure seen in severe COVID-19.
  • The strategy is presented as a potential control measure for severe pediatric COVID-19.

Conclusions:

  • The COVID-19 sepsis bundle offers a structured approach to managing severe cases in children.
  • Early and integrated interventions are crucial for improving outcomes and reducing mortality.
  • This strategy holds promise for controlling severe COVID-19 in pediatric populations.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
528
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
297
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
552
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
422
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
451
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
250